Active_comparator: MASLD screening patients

Patients with requirements of screening following the European Association for the Study of the Liver (EASL) 2016 recommendations. The MASLD screening group will be compounded by patients with at least one of the following criteria:~1. Over fifty years old;~2. Body mass index (BMI) over 25 kg/m2;~3. Diabetes mellitus type 2;~4. Metabolic syndrome; or~5. Persistently elevated liver enzymes.

Other: Controls

Patients without requirements of screening following the European Association for the Study of the Liver (EASL) 2016 recommendations. The control group will be compounded by patients who will not present any of the following criteria:~1. Over fifty years old;~2. Body mass index (BMI) over 25 kg/m2;~3. Diabetes mellitus type 2;~4. Metabolic syndrome; and~5. Persistently elevated liver enzymes.~To be a control participant does not mean that the patient is a healthy participant. The control participants are patients who request any type of endoscopy and fulfil the criteria not to screen for liver steatosis. For example, a 48-year-old male with 21 kg/m2 BMI, without diabetes mellitus type 2, any metabolic syndrome-related comorbidities, with normal liver enzymes and who refused an episode of persistently elevated liver enzymes, with persistent reflux disease after two months of proton pump inhibitor therapy,